Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm

ITCI

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (Nasdaq: ITCI) concerning possible violations of federal securities laws.

If you purchased shares of Intra-Cellular and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

The investigation focuses on whether Intra-Cellular and certain of its officers and/or directors violated federal securities laws. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today